Erelzi (etanercept) is a biologic medicine that helps the pain and swelling of arthritis. It works by blocking TNF (Tumor Necrosis Factor), a type of signalling protein (called a cytokine), that is involved in systemic inflammation. Erelzi belongs to a class of similar medications called Anti-TNF agents.
Erelzi is a type of medicine that is called a biosimilar. A biosimilar is a newer type of biologic medication that is designed to be identical to an existing biologic medication, but is created using a different process. Erelzi is a biosimilar of Enbrel. Both medications are known by the same generic name: etanercept. Biosimilars are often more cost effective than the medications that they replicate.
Erelzi is available as a subcutaneous (under the skin) injection that is usually taken once a week. It is sometimes prescribed for twice a week.
Important Tests and Risks
Erelzi can make it a bit harder for people to fight off infections. People taking this medicine should call their doctor if they have a fever, think they have an infection, or have been prescribed antibiotics to treat an infection.
Patients should coordinate with their doctor to stop treatment before any surgery. It can be re-started once things have healed and there’s no sign of infection.
Patients should discuss all vaccinations with their doctor because some are not advisable to get while taking Erelzi.
It is important to get a TB (tuberculosis) skin test and a chest x-ray before starting Erelzi.
Drug Identification Number (DIN): 02455323, 02455331